Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Three-arm Phase 2 Study Evaluating Two Dose Levels of Microneedle-mediated Delivery of Doxorubicin Compared With a Device-only Control in Patients With Nodular Basal Cell Carcinoma.
Conditions
Interventions
D-MNA 200 mcg
D-MNA 100 mcg
+1 more
Locations
10
United States
Rao Dermotology West Coast -Site #4
Fresno, California, United States
Paradigm Research -Site #6
San Diego, California, United States
Therapeutics Clinical Research -site 08
San Diego, California, United States
Oak Dermotology - site 07
Naperville, Illinois, United States
Arlington Dermatology - Site #1
Rolling Meadows, Illinois, United States
Clinical Trials Management, LLC- Site #5
Mandeville, Louisiana, United States
Start Date
September 3, 2024
Primary Completion Date
March 5, 2026
Completion Date
March 13, 2026
Last Updated
April 2, 2026
NCT07144384
NCT02242929
NCT02018679
Lead Sponsor
SkinJect, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions